According to our latest study on “Autotransfusion Devices Market” Forecast to 2028 – COVID-19 Impact and Global Analysis – by Type, Application, and End-User,” and in the global autotransfusion devices market size is expected to grow from US$ 1,000.26 million in 2021 to US$ 1,331.99 million by 2028; it is estimated to grow at a CAGR of 4.2% from 2021 to 2028. The rapid increase in chronic diseases, rise in transplants, and difficulty in obtaining blood groups across the globe are contributing to the autotransfusion devices market growth.
Claim an exclusive preview of Autotransfusion Devices Market research
https://www.theinsightpartners.com/sample/TIPRE00006521
The rapid spread of the COVID-19 pandemic has provided significant momentum to the autotransfusion device industry in 2020. SARS-CoV-2 (also known as COVID-19) has presented an unprecedented difficulty in several areas of medicine. Since, the beginning of the pandemic millions of patients worldwide have had their care delayed as hospitals canceled non-urgent operations, including some surgeries for people with heart and orthopaedic conditions. A very large number of operations were cancelled or postponed owing to disruption caused by COVID-19. Governments had mitigated against this major burden on patients by developing recovery plans and implementing strategies to restore surgical activity safely. For Instance, according to British Journal of Surgery, an estimated 28,404,603 operations were cancelled or postponed during the peak 12 weeks of disruption due to COVID-19. The overall 12-week cancellation rate accounted to be 72·3%. Although elective surgeries resumed in the UK and many other countries in mid-2020, most hospitals were functioning at considerably reduced capacity, which translates to an ever-lengthening waitlist. As of September, 2020, nearly 140,000 patients in England alone had been waiting for more than a year for their surgeries—100 times the number in 2019. And with a new, highly transmissible variant of SARS-CoV-2 circulating in the UK, resulting in a third national lockdown and further cancellations, patients now face even longer waits.
Furthermore, according to the National Library of Medicine, the decline in the wave was improved to 51% for ophthalmic procedures, 68% for pain procedures, and 49% for orthopedic procedures. The number of electoral processes conducted increased but was still below pre-pandemic standards. Thus, the overall COVID-19 impact on autotransfusion devices market is negative but the market is again gaining traction and expected to grow in coming years.
BD, Braile Biomedica, Fresenius SE & Co. KGaA, Haemonetics Corporation, LivaNova PLC, Medtronic, Redax S.p.A., SARSTEDT AG and Co. KG, Teleflex Incorporated and Zimmer Biomet are a few leading companies operating in the global autotransfusion devices market.
The report segments the autotransfusion devices market as follows:
Based on type, the autotransfusion devices market is segmented into products and accessories. In 2021, accessories segment held the largest autotransfusion devices market share due to rising demand for technologically advanced products in developed and developing economies including the US, Germany, U.K., France, Japan, and others. Moreover, the rising need of autotransfusion to treat chronic diseases such as cardiovascular diseases, cancer, and traumas is likely to drive the market growth in the forecast period. Moreover, the same segment has the highest CAGR in the anticipated period.
The autotransfusion devices market, by application, is segmented into cardiac surgeries, orthopedic surgeries, organ transplantation, trauma procedures, and others. The cardiac surgeries segment held the largest share of the market in 2021, while the organ transplantation segment is also estimated to register the highest CAGR in the market during the forecast period.
By end-user, the autotransfusion devices market is segmented into hospitals, specialty clinics, and ambulatory surgical centers. The hospitals segment held largest share of the autotransfusion devices market in 2021, likely to continue its dominance in the market during the forecast period. However, the ambulatory surgical centers segment is anticipated to register the highest CAGR in the autotransfusion devices market during the forecast period.
By geography, the autotransfusion devices market is segmented into North America, Europe, Asia Pacific (APAC), the Middle East & Africa (MEA), and South & Central America (SCAM). The autotransfusion device market in North America is segmented into the US, Canada, and Mexico. The autotransfusion device market in Europe is segmented into France, Germany, the UK, Spain, Italy, and the Rest of Europe. The autotransfusion device market in Asia Pacific (APAC) is segmented Into China, India, Japan, Australia, South Korea, and the Rest of Asia Pacific. The autotransfusion device market in the Middle East & Africa (MEA) is segmented Into Saudi Arabia, the UAE, South Africa, and the Rest of the Middle East & Africa. The autotransfusion device market in South and Central America (SCAM) is segmented into Brazil, Argentina, and the Rest of South and Central America.
About Us:
TIP is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.
Contact Us:
If you have any queries about this report or if you would like further information, please contact us:
Contact Person: Ankit Mathur
E-mail: [email protected]
Phone: +1-646-491-9876
About Author
